Eupraxia Pharmaceuticals (EPRX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.23
- Surprise
- —
- Score today
- 5.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates EPRX Sell at 5.3/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-03.
What argues against it
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $7.74
- Price target
- $14.22
- Stop
- $7.20
- Upside to target
- +83.7%
- Reward-to-risk
- 5.6:1
Risk check: trading volume is running 1.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
EPRX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $511.4M
- P/E (fwd)
- -7.5
- 52-week range
- $5.25–$9.32
- Off 52-week high
- 17.0%
- RSI (14)
- 46
- Volume vs avg
- 1.91×
- Score today
- 5.3/10